Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway
Open Access
- 29 December 2008
- journal article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 27 (1) , 86
Abstract
Background: The antiangiogenic agent cilengitide disrupts integrin binding to the extracellular matrix leading to apoptosis of activated endothelial cells. Integrins are also widely expressed in malignant glioma and integrin inhibitors may directly target tumor cells in this disease. Aim of the current study was to investigate effects of cilengitide on endothelial and glioma cells on molecular and cellular levels. Results: Cilengitide caused dose-dependent detachment of endothelial cells from cell culture dishes. Proliferation of endothelial cells was significantly inhibited while the proportion of apoptotic cells was increased. Incubation of integrin-expressing glioma cells with cilengitide caused rounding and detachment after 24 hours as observed with endothelial cells. Cilengitide inhibited proliferation and induced apoptosis in glioma cells with methylated MGMT promotor when given alone or in combination with temozolomide. In endothelial as well as glioma cells cilengitide inhibited phosphorylation of FAK, Src and Akt. Assembly of cytoskeleton and tight junctions was heavily disturbed in both cell types. Conclusion: Cilengitide inhibits integrin-dependent signaling, causes disassembly of cytoskeleton, cellular detachment and induction of apoptosis in endothelial and glioma cells thereby explaining the profound activity of integrin inhibitors in gliomas. The combination of cilengitide with temozolomide exerted additive effects in glioma cells as observed clinically.Keywords
This publication has 43 references indexed in Scilit:
- Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumorsAnnals of Oncology, 2007
- Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitroBiochemical and Biophysical Research Communications, 2007
- Fak/Src signaling in human intestinal epithelial cell survival and anoikis: Differentiation state‐specific uncoupling with the PI3‐K/Akt‐1 and MEK/Erk pathwaysJournal of Cellular Physiology, 2007
- EFFECT OF THE ANGIOGENESIS INHIBITOR CILENGITIDE (EMD 121974) ON GLIOBLASTOMA GROWTH IN NUDE MICENeurosurgery, 2006
- Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cellsBlood, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- IS20I, a Specific ??v??3 Integrin Inhibitor, Reduces Glioma Growth in VivoNeurosurgery, 2003
- αvβ3 and αvβ5 Integrin Expression in Glioma PeripheryNeurosurgery, 2001
- N-Methylated Cyclic RGD Peptides as Highly Active and Selective αVβ3Integrin AntagonistsJournal of Medicinal Chemistry, 1999
- Requirement of Vascular Integrin α v β 3 for AngiogenesisScience, 1994